SKiN-HUID (Q4297324): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
||
| Property / contained in NUTS | |||
| Property / contained in NUTS: Arrondissement of Ghent / rank | |||
Normal rank | |||
Revision as of 09:02, 17 June 2022
Project Q4297324 in Belgium, Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | SKiN-HUID |
Project Q4297324 in Belgium, Netherlands |
Statements
1,505,489.43 Euro
0 references
3,010,978.86 Euro
0 references
50.0 percent
0 references
1 September 2016
0 references
31 August 2019
0 references
Universiteit Maastricht
0 references
51°1'4.26"N, 3°41'29.69"E
0 references
51°13'20.82"N, 4°24'36.40"E
0 references
51°3'13.10"N, 5°50'44.20"E
0 references
50°50'6.50"N, 5°42'58.46"E
0 references
50°58'58.22"N, 5°48'12.20"E
0 references
Cancer is one of the most threatening diseases of this century, causing eight million deaths worldwide each year. Cancer's complexity means the disease can only be treated through innovation and translating knowledge into new medication. Under the direction of the University of Maastricht, the University of Antwerp, Basic Pharma Technologies, MosaMedix and VIB are seeking to meet the specific challenges of cancer. At Euregional PACT, a virtual research laboratory set up through the previous Interreg programme, a number of basic medical technologies have already been developed at academic level. One of those technologies is the Anx-A5-based platform for Target Drug Delivery. It involves targeted administration of medicines via electrical or hypothermic stimulation, which exerts stress on the cells. Advantages of this technique are the efficient, targeted coupling of toxic pharmaceutical quantities, but on the basis of reduced doses so that general side-effects remain limited and the patient's quality of life is maintained. The aim is to further expand this technology within SKiN-HUID into a therapy, through preclinical and clinical validation. A stimulation device with applicator will be developed that is to be used for preclinical validation of the treatment. The Annexine A5-ETA-based medicine is also being further developed to enable targeted, efficient administration by means of the device and the applicator. (English)
0 references